Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction

Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression

Zydus announces completion of Enrolment for Phase II clinical trial of Usnoflast

ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset

Swixx Biopharma acquires Biopas to expand in Latin America

The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies

BaseLaunch announces a new partnership with AbbVie

Further strengthens BaseLaunch's global pharma industry partnerships

Merck to acquire life science company Mirus Bio for US$ 600 million

Acquisition will advance Merck’s integrated offering for viral vector manufacturing

Glenmark and BeiGene ink agreement for marketing and distribution of Tislelizumab and Zanubrutinib in India

AstraZeneca sets ambition to deliver US$ 80 billion revenue by 2030

Launch of 20 new medicines expected by 2030

Biocon Biologics’ receives FDA approval for Biosimilar Aflibercept for Yesafili

The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States

Modular ATP study of the mCRM System meets primary safety and efficacy endpoints

Additional data from APPRAISE ATP trial reinforce modular therapy approach

IIHMR Start-ups inks MoU with BMCHRC & HCG Hospital

The collaboration aims to bolster healthcare entrepreneurship